Company Description
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody.
The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 167 |
| CEO | Leon Moulder |
Contact Details
Address: 852 Winter Street, Suite 250 Waltham, Massachusetts 02451 United States | |
| Phone | 857 271 2954 |
| Website | zenasbio.com |
Stock Details
| Ticker Symbol | ZBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1953926 |
| CUSIP Number | 98937L105 |
| ISIN Number | US98937L1052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph L. Farmer | Chief Operating Officer and President |
| Dr. Heinrich Schlieker Ph.D. | Chief Technical Officer |
| Dr. Haley Laken Ph.D. | Chief Scientific Officer |
| Caroline Chevalier | Chief Administrative Officer |
| Jeffrey Held | Chief Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 16, 2026 | ARS | Filing |
| Mar 16, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 16, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 16, 2026 | 10-K | Annual Report |
| Mar 16, 2026 | 8-K | Current Report |
| Feb 13, 2026 | 8-K | Current Report |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 28, 2026 | 424B7 | Filing |
| Jan 14, 2026 | SCHEDULE 13D | Filing |